Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study
about
Nebulised dornase alfa versus placebo or hypertonic saline in adult critically ill patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysisSelecting and measuring optimal outcomes for randomised controlled trials in surgeryStress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysisThe paradox of bardoxolone methyl: a call for every witness on the stand?Use of n-3 PUFAs can decrease the mortality in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis.Scandinavian SSAI clinical practice guideline on choice of first-line vasopressor for patients with acute circulatory failureBenchmarks for detecting 'breakthroughs' in clinical trials: empirical assessment of the probability of large treatment effects using kernel density estimation.Medication reviews for nursing home residents to reduce mortality and hospitalization: systematic review and meta-analysisPeri-operative pulse oximetry in low-income countries: a cost-effectiveness analysis.The geko™ electro-stimulation device for venous thromboembolism prophylaxis: a NICE medical technology guidanceST waveform analysis versus cardiotocography alone for intrapartum fetal monitoring: a systematic review and meta-analysis of randomized trials.Recognizing Differences in Hospital Quality Performance for Pediatric Inpatient CarePostmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study.Use of surrogate outcomes in US FDA drug approvals, 2003-2012: a survey.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in Europe.Are outcomes reported in surgical randomized trials patient-important? A systematic review and meta-analysis.Neuromonitoring in thyroidectomy: a meta-analysis of effectiveness from randomized controlled trials.Enteral omega-3 fatty acid supplementation in adult patients with acute respiratory distress syndrome: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis.Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.Epidural analgesia in patients with traumatic rib fractures: a systematic review of randomised controlled trials.Extracorporeal carbon dioxide removal in patients with chronic obstructive pulmonary disease: a systematic review.Outcomes of laparoscopic gastric bypass in a randomized clinical trial compared with a concurrent national database.Statistical significance is not necessarily equal to clinical significance.JPEN Journal Club 4. Using surrogate outcomes.Prospective, randomized and controlled trial on magnesium sulfate administration during laparoscopic gastrectomy: effects on surgical space conditions and recovery profiles.Venous-to-arterial carbon dioxide difference: an experimental model or a bedside clinical tool?Untargeted antifungal therapy in adult patients with complicated intra-abdominal infection: a systematic review.Therapeutic bronchoscopy vs. standard of care in acute respiratory failure: a systematic review.Doing it hard in the bush: Aligning what gets measured with what matters.Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.A methodology review on the incremental prognostic value of computed tomography biomarkers in addition to Framingham risk score in predicting cardiovascular disease: the use of association, discrimination and reclassification.Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.Avoidable waste of research related to outcome planning and reporting in clinical trials.A randomised controlled trial is not a pilot trial simply because it uses a surrogate endpoint
P2860
Q26778569-BD395427-4C8C-4ACB-91BB-4FE1D05D90DCQ26851180-86F5B3AA-D3ED-4F66-9797-75ECDC58FC6BQ28300556-E017A603-BB72-464C-B5E0-99FB4E9B5703Q33358784-563E2763-5923-4435-A4B4-C5ADF9C53108Q34043807-72DEF54C-73AA-4509-A699-05980C3D5497Q34047325-45FC5F34-842C-496A-B0ED-96D86938F16AQ34397235-4C986BBB-7E02-4D38-8295-97235304B4C9Q34571024-968075E0-A6BC-48C8-BD6C-D04A33141F0AQ34686808-3824C4AB-B5D6-4DBA-B715-404CCBAC1905Q35225401-F353B725-365D-4758-8BA8-6EA66EFAE6E1Q35853595-ED45EC7A-BA55-40DF-85BF-ED2DB6BF2EC7Q35894738-CE518F95-F316-49C5-8B89-9054E4FE7FA5Q36121661-4CDBEE50-A2D5-409E-BE31-183A617BBEDBQ36329179-8F72AA20-AF02-4AB3-A8BB-A27C3FEB85B0Q36525431-344CBF0F-9A1B-4557-84DD-774D488AA5F0Q37411577-FC14C1C6-2FC9-4B69-8A43-2C243EBF8453Q37730441-1877208D-EA25-4D16-BB79-D872EF8CF347Q38107425-AD537770-9080-47C0-B637-968DDBCC70F7Q38189978-F8370525-D5D7-41E9-9CEF-8445CE08D224Q38259501-7B3C94ED-7700-47D8-AD66-C28727414D13Q38312486-5DDCCCBF-D298-4C1D-B2D3-EBD7F10DB747Q38356381-2DCC9D06-D26D-43CF-8F9F-E45E82A8C856Q38537445-5F97685F-003B-4C3D-B51F-EABDE98AE0E5Q38940580-8DB3EEE3-1659-4EA8-A5D7-FEAE8E86D87BQ45938987-29F58C12-E522-4FB0-BD32-DDAA764C716AQ46524976-7CE1BC4A-1DAB-47B9-B87D-BB2176C9BE5BQ47372702-166EC506-260E-4170-930D-5C9EE8775CDBQ47614330-14168998-3833-45BE-B66E-F14A13EAEA21Q47619531-58B3F7A9-6F9D-4954-881E-968CD2C7BCD9Q47750410-22BEC209-5276-4B01-9C87-BDAC6F594289Q47987963-AA262A98-E356-48EE-8B27-EA6F01C0C97BQ48196689-77D4A183-649E-44A7-910C-77C1F98B583FQ50205884-2BF78001-CDF1-4441-82EC-985E7CC1FBCBQ50318034-AA0969D6-4314-4C57-A700-C32E8F90E4ADQ52644314-FA452338-2480-4700-A3B8-21513E8446CDQ55475456-57EE29FF-9AE1-407A-B11A-336D6FDE7603Q57493444-867EBF79-9C7E-4122-B49D-A130EF0BD50D
P2860
Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparison of treatment effect ...... ls: meta-epidemiological study
@ast
Comparison of treatment effect ...... ls: meta-epidemiological study
@en
Comparison of treatment effect ...... ls: meta-epidemiological study
@nl
type
label
Comparison of treatment effect ...... ls: meta-epidemiological study
@ast
Comparison of treatment effect ...... ls: meta-epidemiological study
@en
Comparison of treatment effect ...... ls: meta-epidemiological study
@nl
prefLabel
Comparison of treatment effect ...... ls: meta-epidemiological study
@ast
Comparison of treatment effect ...... ls: meta-epidemiological study
@en
Comparison of treatment effect ...... ls: meta-epidemiological study
@nl
P2860
P50
P921
P356
P1433
P1476
Comparison of treatment effect ...... ls: meta-epidemiological study
@en
P2093
P2860
P356
10.1136/BMJ.F457
P407
P577
2013-01-29T00:00:00Z